TAILIEUCHUNG - Effects of an oral mucosa protective formulation on chemotherapy- and/ or radiotherapy-induced oral mucositis: A prospective study

Oral mucositis (OM) associated with cancer treatment not only impairs patients’ quality of life but also causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of Episil® oral liquid, which is an approved protective formulation for the oral mucosa in patients with OM. The extent of the pain-relieving efect, feeling during use, and adverse events or problems were evaluated. | Ueno et al. BMC Cancer 2022 22 90 https s12885-021-09107-6 RESEARCH Open Access Effects of an oral mucosa protective formulation on chemotherapy and or radiotherapy induced oral mucositis a prospective study Takao Ueno1 Wakako Yatsuoka1 Hiroto Ishiki2 Kanako Miyano3 and Yasuhito Uezono3 4 5 Abstract Background Oral mucositis OM associated with cancer treatment not only impairs patients quality of life but also Episil oral liquid which is an approved protective formulation for the oral mucosa in patients with OM. The extent of causes treatment delays or changes. This prospective exploratory study was conducted to evaluate the efficacy of the pain-relieving effect feeling during use and adverse events or problems were evaluated. Methods In total 10 Japanese cancer patients with OM receiving chemotherapy pretreatment therapy for hemat- opoietic stem cell transplantation or radiation therapy for head and neck cancer were enrolled. mean NRS began to decrease at 5 min after using Episil to p . A significant decrease was Results A numerical rating scale NRS was used to assess oral pain intensity due to OM. Compared to baseline the observed in the pain score after using Episil compared with that before using Episil and this effect lasted up to 120 min. The protective effects of Episil were observed 3 5 min after application. Some patients felt slight soreness or discomfort when applying Episil . However this discomfort due to Episil s stimulation was within the allowable range and transient. No adverse events were observed in any of the cases. Conclusions The results of this prospective study showed that Episil could be an effective treatment to relieve oral pain in Japanese patients with moderate to severe OM and this newly approved product might adequately support patients oral intake. Trial registration University Hospital Medical Information Network Clinical Trials Registry UMIN-CTR UMIN0 00031 921 . Keywords Bioadhesive .

• Y khoa - Dược
• BMC Cancer
• Breakthrough pain
• Opioid analgesics
• Oral mucositis
• Cancer treatment
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Head and neck cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study